Biotech Values

[poorgradstudent]

>Does CPOP expand the potential for such regimens? <

I have no hard data to answer this question right now. However, I do project that the answer will be yes. The important factor is the tolerability of pixantrone versus doxorubicin. The latter is well known to have cumulative cardiac toxicity in humans due to exacerbation of free radical-derived damage. This has seriously limited doxorubicin use / retreatment in the clinic. To date, pix appears to be much more benign with respect to this serious side effect. Therefore, approval of pix may open up retreatment regimens that were not previously an option with dox.

Additional commercial opportunities lie in breast, ovarian and some blood cancers. CTIC has some heavy lifting to do in order to introduce pix as a softer, gentler doxorubicin. However, the economic benefits will be worth the effort.